<DOC>
	<DOCNO>NCT02217631</DOCNO>
	<brief_summary>The objective trial ass safety , tolerability , pharmacokinetics , pharmacodynamics multiple rise dos BI 653048 BS H3PO4 compare prednisolone .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics BI 653048 BS H3PO4 Capsule Multiple Rising Doses Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Healthy male subject base complete medical history , physical examination , vital sign ( blood pressure pulse rate ) , 12lead ECG , clinical laboratory test Age 18 50 year Body mass index ( BMI ) 18.5 29.9 kg/m2 Signed date write informed consent accordance Good Clinical Practice local legislation Any clinically relevant deviation normal medical examination include blood pressure , pulse rate , ECG Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) , psychiatric disorder , neurological disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 h ) within least 1 month less 10 halflives respective drug first treatment study drug trial Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day first treatment study drug trial Participation another trial investigational drug within 30 day first treatment study drug trial Smoker ( 10 cigarette , 3 cigar , 3 pipe per day ) Inability refrain smoke begin 1 day first treatment study drug discharge clinical unit Alcohol abuse ( 60 gram per day ) Drug abuse Blood donation 100 mL within 4 week first treatment study drug trial Excessive physical activity within 1 week first treatment study drug trial Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g . QTc interval repeatedly longer 450 m ) A history additional risk factor torsades de point ( e.g . heart failure , hypokalaemia , family history Long QT syndrome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>